Table 2.
Response rate to cetuximab plus FOLFOX‐4 in KRAS wild‐type colorectal carcinoma patients with different epidermal growth factor receptor codon 521 statuses (n = 112)
| Response | G/G (wild‐type) (%) | G/A or A/A (%) | P |
|---|---|---|---|
| All patients enrolled | 36 (100) | 76 (100) | |
| OR (CR + PR) | 20 (55.6) | 60 (78.9) | 0.01 |
| CR | 2 (5.6) | 3 (3.9) | |
| PR | 18 (50.0) | 57 (75.0) | |
| SD | 9 (25.0) | 11 (14.5) | |
| PD | 7 (19.4) | 5 (6.6) |
Comparison of overall response rate between patients with different EGFR R521K polymorphisms. CR, complete remission; OR, overall response; PD, progressive disease; PR, partial remission; SD, stable disease.